Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Estrogen Receptor and Progesterone Receptor Status in Breast Cancer in Relation to Age, Histological Grade, Size of Lesion and Lymph Node Involvement

  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Introduction: Breast cancer is the most common malignancy of women in Kashmir. This study was conducted with the objective of assessing hormone receptor positivity and its correlation with age at diagnosis, tumor size, histological grade and lymph node metastasis. Materials and Methods: 132 newly diagnosed cases of invasive breast cancer diagnosed at the Department of Pathology, SKIMS, Srinagar, J&K, were included after excluding biopsies, in-situ lesions and recurrence cases. Results: Mean age of the patients was 48.2 years, 59.1% being ${\leq}50$ years of age. Mean duration of symptoms was 6.32 months. Most lesions (65.1%) were 2-5 cm and 16.7% were ${\geq}5.0$ cm in greatest dimension. The predominant (80.3%) morphology was IDC-NOS. The majority of the cases presented as grade II (52.1%) lesions and lymph node involvement was present in 65.2%. ER and PR were positive in 66.3% and 63.4% cases, respectively, increasing with rising age. High grade lesions and larger size tumors were more likely to be ER and PR negative. No correlation was found between ER/PR status and lymph node metastasis. Conclusions: ER and PR expression in breast cancers in the current study was found to be higher than studies done in India/Asia but lower than studies conducted in the West, even on Indian/Asian immigrants. Markedly lower receptor expression in Indian/Asian studies is likely due to preanalytic variables, thresholds for positivity, and interpretation criteria. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer are strongly advocated for standardization of receptor evaluation and for clinical management of breast cancer patients to provide best therapeutic options.

Keywords

References

  1. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003). Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol, 21, 1973-9. https://doi.org/10.1200/JCO.2003.09.099
  2. Barnes Dm, Hanby Am (2001). Oestrogen And Progesterone Receptors In Breast Cancer: Past, Present And Future. Histopathology, 38, 271-4. https://doi.org/10.1046/j.1365-2559.2001.01060.x
  3. Blesch KS, Davis F, Kamath SK (1999). A comparison of breast and colon cancer incidence rates among native Asian Indians, US immigrant Asian Indians, and whites. J Am Diet Assoc, 99, 1275-7. https://doi.org/10.1016/S0002-8223(99)00313-2
  4. Bolufer P, Molina R, Ruiz A, et al (1994). Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer. Clin Chim Acta, 229, 107-22. https://doi.org/10.1016/0009-8981(94)90233-X
  5. Couris CM, Polazzi S, Olive F, et al (2009). Breast cancer incidence using administrative data: correction with sensitivity and specificity. J Clin Epidemiol, 62, 660-6. https://doi.org/10.1016/j.jclinepi.2008.07.013
  6. Deapen D, Liu L, Perkins C, Bernstein L, Ross RK (2002). Rapidly rising breast cancer incidence rates among Asian-American women. Int J Cancer, 99, 747-50. https://doi.org/10.1002/ijc.10415
  7. Desai SB, Moonim MT, Gill AK, et al (2000). Hormone receptor status of breast cancer in India: a study of 798 tumors. Breast, 9, 267-70. https://doi.org/10.1054/brst.2000.0134
  8. Deshpande AD, Jeffe DB, Gnerlich J, et al (2009). Racial Disparities in Breast Cancer Survival: An Analysis by Age and Stage. J Surg Res, 153, 105-13. https://doi.org/10.1016/j.jss.2008.05.020
  9. Dunnwald LK, Rossing MA, Li CI (2007). Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res, 9, R6. https://doi.org/10.1186/bcr1639
  10. Early Breast Cancer Trialists' Collaborative Group (1998). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 35, 1451-67.
  11. Fact Sheet No. 297: Cancer. World Hlth Organization. February 2006. Retrieved 2009-03-26.
  12. Fatima, TWO AUTHOR, et al (2005). Breast cancer: steroid receptors and other prognostic indicators. J Coll Physicians Surg Pak. 15, 230-3.
  13. Fisher ER, Anderson S, Dean S, et al (2005). Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer, 103, 164-73. https://doi.org/10.1002/cncr.20761
  14. Gajalakshmi P, Natarajan TG, Selvi Rani D, Thangaraj K (2007). A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer. Breast Cancer Res Treat, 101, 3-6. https://doi.org/10.1007/s10549-006-9267-z
  15. Ghumare SS, Cunningham JE (2007). Breast cancer trends in Indian residents and emigrants portend an emerging epidemic for India. Asian Pac J Cancer Prev, 8, 507-12.
  16. Goggins WB, Wong G (2009). Cancer among Asian Indians/ Pakistanis living in the United States: low incidence and generally above average survival. Cancer Causes Control, 20, 635-43. https://doi.org/10.1007/s10552-008-9275-x
  17. Goldhirsch A, Glick JH, Gelber RD, et al (2005). Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol, 16, 1569-83. https://doi.org/10.1093/annonc/mdi326
  18. Gown MA (2008). Current issues in ER and HER2 testing by IHC in breast cancer, Modern Pathol, 21, 8-15. https://doi.org/10.1038/modpathol.2008.34
  19. Hammond ME, Hayes DF, Dowsett M, et al (2010). American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer arch pathol lab med. Arch Pathol Lab Med, 134, 907-22.
  20. Harvey JM, Clark GM, Osborne CK, et al (1999). Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, 17, 1474-81
  21. Hawkins RA, Roberts MM, Forrest APM (1980). Estrogen receptors and breast cancer. Current status. Br J Surg, 67, 162-5.
  22. Hebert JR, Ghumare SS, Gupta PC (2006). Stage at diagnosis and relative differences in breast and prostate cancer incidence in India: comparison with the United States. Asian Pac J Cancer Prev, 7, 547-55.
  23. Irvin WJ Jr, Carey LA (2008). What is triple-negative breast cancer? Eur J Cancer, 44, 2799-805. https://doi.org/10.1016/j.ejca.2008.09.034
  24. Jack RH, Davies EA, Moller H (2009). Breast cancer incidence, stage, treatment and survival in ethnic groups in South East England. Br J Cancer, 100, 545-50. https://doi.org/10.1038/sj.bjc.6604852
  25. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  26. Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE (2010). Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. - a SEER analysis. BMC Cancer, 10, 191. https://doi.org/10.1186/1471-2407-10-191
  27. Kamath SK, Murillo G, Chatterton RT Jr, et al (1999). Breast cancer risk factors in two distinct ethnic groups: Indian and Pakistani vs. American premenopausal women. Nutr Cancer, 35, 16-26. https://doi.org/10.1207/S1532791416-26
  28. Kuraparthy S, Reddy KM, Yadagiri LA, et al (2007). Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India. World J Surg Oncol, 5, 56. https://doi.org/10.1186/1477-7819-5-56
  29. La Vecchia C, Franceschi S, Lucchini F, Levi F (1994). International variations and trends in the incidence of breast Cancer in Older Women. Cancer Control, 1, 327-33.
  30. Marugame T, Katanoda K (2006). International comparisons of cumulative risk of breast and prostate cancer, from cancer incidence in five continents Vol. VIII. Jpn J Clin Oncol, 36, 399-400. https://doi.org/10.1093/jjco/hyl049
  31. Mohsin SK, Weiss H, Havighurst T, et al (2004). Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol, 17, 1545-54. https://doi.org/10.1038/modpathol.3800229
  32. Morabia A, Costanza MC (2000). Reproductive factors and incidence of breast cancer: an international ecological study. Soz Praventivmed, 45, 247-57. https://doi.org/10.1007/BF01591687
  33. Mori I, Yang Q, Kakudo K (2002). Predictive and prognostic markers for invasive breast cancer. Pathol Int, 52, 186-94 https://doi.org/10.1046/j.1440-1827.2002.01335.x
  34. Mudduva LK (2009). Quick score of hormone receptor status of breast carcinoma: correlation with other clinicopathological prognostic parameters. Indian J Pathol Microbiol, 52, 159-63 https://doi.org/10.4103/0377-4929.48906
  35. Murthy NS, Agarwal UK, Chaudhry K, Saxena S (2007). A study on time trends in incidence of breast cancer - Indian scenario. Eur J Cancer Care, 16, 185-6 https://doi.org/10.1111/j.1365-2354.2006.00761.x
  36. Naeem M, Khan N, Aman Z, et al (2008). Pattern of breast cancer: experience at lady reading hospital, Peshawar J Ayub Med Coll Abbottabad, 20, 22-5.
  37. Navani S, Bhaduri AS (2005). High incidence of oestrogen receptor negative progesterone receptor positive phenotype in Indian breast cancer: Fact or fiction? Indian J Pathol Microbiol, 48, 199-201
  38. Nguyen Pl, Taghian AG, Katz MS, et al (2008). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and Her-2 is associated with local and distant recurrence after breast- conserving therapy. J Clin Oncol, 26, 2373-8. https://doi.org/10.1200/JCO.2007.14.4287
  39. Nielsen To, Hsu Fd, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74. https://doi.org/10.1158/1078-0432.CCR-04-0220
  40. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009). Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res 7, 4-13. https://doi.org/10.3121/cmr.2009.825
  41. Parkin Dm, Bray F, Ferlay J, Pisani P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94, 153-6. https://doi.org/10.1002/ijc.1440
  42. Perou Cm, Sorlie T, Eisen Mb, et al (2000). Molecular portraits of human breast tumours. Nat, 406, 747-52. https://doi.org/10.1038/35021093
  43. Raina V, Bhutani M, Bedi R, et al (2005). Clinical features and prognostic factors of early breast cancer at a major cancer center in North India. Indian J Cancer, 42, 40-5 https://doi.org/10.4103/0019-509X.15099
  44. Raju GC, Naraynsingh V (1989). Breast cancer in West Indian women in trinidad. Trop Geogr Med, 41, 257-60.
  45. Rambau PF, Chalya PL, Manyama MM, Jackson KJ (2011). Pathological features of breast cancer seen in Northwestern Tanzania: a nine years retrospective study. BMC Res Notes, 4, 214 https://doi.org/10.1186/1756-0500-4-214
  46. Rampaul RS, Pinder SE, Elaston CW, Ellis IO (2001). Prognostic and predictive factors in primary breast cancer and their role in patient management; the Nottingham breast team. Eur J Surg Oncol, 27, 229-38 https://doi.org/10.1053/ejso.2001.1114
  47. Rao R, Kuerer H, Cristofanilli M, et al (2008). Breast cancer in the asian Indian population of the United States: a call for screening and education. Breast J, 14, 402-3. https://doi.org/10.1111/j.1524-4741.2008.00613.x
  48. Rastogi T, Devesa S, Mangtani P, et al (2008). Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol, 37, 147-60. https://doi.org/10.1093/ije/dym219
  49. Rosen M, Lundin A, Nystrom L, et al (2000). (Incidence and mortality of breast cancer during a 25-year period. International and regional comparisons). Lakartidningen, 97, 294-9.
  50. Setiawan VW, Monroe KR, Wilkens LR, et al (2009). HendersonBreast cancer risk factors defined by estrogen and progesterone receptorstatus. Am J Epidemiol, 169, 1251-9. https://doi.org/10.1093/aje/kwp036
  51. Shet, TWO AUTHOR, et al (2009). Hormone receptors over last 8 years in a cancer referral center in India: What was and what is?. Indian J Pathol and Microbiology, 52, 171-4 https://doi.org/10.4103/0377-4929.48909
  52. Sorlie T, Perou Cm, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. https://doi.org/10.1073/pnas.191367098
  53. Sorlie T, Tibshirani R, Parker J, et al (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100, 8418-23. https://doi.org/10.1073/pnas.0932692100
  54. Sotiriou C, Neo Sy, Mcshane Lm, et al (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA, 100, 10393-8. https://doi.org/10.1073/pnas.1732912100
  55. Suvarchala SB, Nageswararao R(2011). Carcinoma Breast histopathological and hormone receptors correlation. J Biosci Tech, 2, 340-8
  56. World Cancer Report. International Agency For Research On Cancer. June 2003. Retrieved 2009-03-26.
  57. Wu TY, West B, Chen YW, Hergert C (2006). Health beliefs and practices related to breast cancer screening in Filipino, Chinese and Asian-Indian women. Cancer Detect Prev, 30, 58-66. https://doi.org/10.1016/j.cdp.2005.06.013

Cited by

  1. Prognostic Significance of Interactions Between ER Alpha and ER Beta and Lymph Node Status in Breast Cancer Cases vol.14, pp.10, 2013, https://doi.org/10.7314/APJCP.2013.14.10.6081
  2. Is Axillary Dissection Necessary for Breast Cancer in Old Women? A Meta-analysis of Randomized Clinical Trials vol.14, pp.2, 2013, https://doi.org/10.7314/APJCP.2013.14.2.947
  3. Loss of Expression and Aberrant Methylation of the CDH1 (E-cadherin) Gene in Breast Cancer Patients from Kashmir vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6397
  4. Clinico-Morphological Profile and Receptor Status in Breast Cancer Patients in a South Indian Institution vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7839
  5. Hypofractionated Radiotherapy for Breast Cancers - Preliminary Results from a Tertiary Care Center in Eastern India vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2505
  6. MDA-MB-231 Human Breast Cancer Cells by RhoGDI-α Silencing and Overexpression vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3311
  7. Descriptive Study on Selected Risk Factors and Histopathology of Breast Carcinoma in a Tertiary Care Centre in Kerala, India with Special Reference to Women Under 40 Years Old vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.181
  8. BreastLight Apparatus Performance in Detection of Breast Masses Depends on Mass Size vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1181
  9. Association between GSTP1 Genotypes and Hormone Receptor Phenotype in Invasive Ductal Carcinomas of Breast vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1707
  10. Reduced expression levels of let‑7c in human breast cancer patients pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.2877
  11. The pattern of prognostic and risk indicators among women with breast cancer undergoing modified radical mastectomy in Dar es Salaam, Tanzania vol.11, pp.1, 2016, https://doi.org/10.1186/s13027-016-0075-8
  12. Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Muhimbili National Hospital, Dar es salaam, Tanzania vol.12, pp.1, 2017, https://doi.org/10.1186/s13027-017-0170-5
  13. Patterns of Care of Breast Cancer Patients in a Rural Cancer Center in Western India vol.9, pp.3, 2018, https://doi.org/10.1007/s13193-018-0748-4